RemeGen Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS30
PHASE 3 / 2-314
RECRUITING21
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO60%
Delay Index: of 10 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →
Open RemeGen Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Capecitabine NCT06155383 |
P2 | Recruiting | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | 90 | 2025-01-31 |
| Disitamab Vedotin for Injection NCT06389006 |
P2 | Recruiting | Breast Cancer | 79 | 2025-06-01 |
| RC48-ADC(2.5mg/kg) NCT05980481 |
P2/3 | Active, not recruiting | Gastric Cancer | 201 | 2025-07-10 (+12 mo) |
| RC118-ADC NCT05205850 |
P1/2 | Recruiting | Advanced Solid Tumor | 135 | 2025-09-30 |
| Disitamab Vedotin Injection (18 weeks) NCT06227117 |
P2 | Recruiting | Breast Cancer | 120 | 2025-12 |
| RC48-ADC in Combination with gemcitabine NCT05943379 |
P2 | Recruiting | NMIBC | 85 | 2025-12-01 |
| RC148 Monotherapy NCT06016062 |
P1/2 | Recruiting | Solid Tumor | 221 | 2025-12-31 (+12 mo) |
| RC108 NCT06962865 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 80 | 2026-05-31 |
| Disitamab Vedotin Injection NCT06178159 |
P2 | Recruiting | Breast Cancer | 40 | 2026-06 (+18 mo) |
| Telitacicept NCT05799287 |
P3 | Active, not recruiting | Primary IgA Nephropathy | 318 | 2026-06 (+8 mo) |
| Disitamab Vedotin NCT06642545 |
P2 | Recruiting | Breast Cancer | 40 | 2026-10-01 |
| Disitamab Vedotin Injection NCT06221748 |
P2/3 | Recruiting | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | 90 | 2026-12 |
| RC48-ADC NCT05302284 |
P3 | Recruiting | Urothelial Carcinoma; HER2-expressing | 452 | 2026-12-31 |
| Telitacicept NCT07249632 |
P3 | Recruiting | Myasthenia Gravis, Ocular | 120 | 2026-12-31 |
| RC148 (Dose 1) plus Capecitabine and Oxaliplatin NCT07462143 |
P2/3 | Recruiting | Colorectal (Colon or Rectal) Cancer | 80 | 2027-05-12 |
| Disitamab Vedotin NCT06155396 |
P2 | Recruiting | Cervical Cancer | 116 | 2027-06-30 |
| Telisotuzumab adizutecan plus RC148(ABBV-1480) NCT07874282 |
P2 | Not yet recruiting | Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology | 200 | 2027-12 |
| RC48-ADC NCT05745740 |
P1/2 | Not yet recruiting | Non-small Cell Lung Cancer | 26 | 2027-12-01 (+24 mo) |
| RC48-ADC NCT04400695 |
P3 | Recruiting | Breast Cancer | 366 | 2027-12-31 (+62 mo) |
| RC148 plus Carboplatin and Paclitaxel NCT07416474 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 574 | 2027-12-31 |
| RC278 NCT07105215 |
P1/2 | Recruiting | Solid Tumors | 312 | 2027-12-31 |
| Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine NCT06944496 |
P3 | Not yet recruiting | Gastric Carcinoma | 616 | 2028-05-15 |
| RC148 plus Telisotuzumab adizutecan NCT07895355 |
P2 | Not yet recruiting | Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy | 412 | 2028-07 |
| RC28-E NCT07936487 |
P3 | Not yet recruiting | Diabetic Macular Edema (DME); wAMD | 350 | 2028-12-01 |
| Disitamab Vedotin for injection NCT06378242 |
P1/2 | Recruiting | High-risk Non-muscle Invasive Bladder Cancer | 24 | 2029-03-15 |
| Telitacicept NCT07495033 |
P3 | Not yet recruiting | CTD-ILD | 260 | 2029-05-31 |
| Disitamab Vedotin NCT07315750 |
P3 | Recruiting | Gastric Carcinoma | 555 | 2029-06-30 |
| RC288 For Injection NCT07537881 |
P1/2 | Recruiting | Solid Tumors | 326 | 2029-12-30 |
| RC118(Dose 1) plus RC148(Dose 1) NCT07935369 |
P2/3 | Not yet recruiting | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | 680 | 2030-04-30 |
| RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection NCT07829549 |
P3 | Recruiting | Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | 540 | 2031-04 |